Immune dysregulation and drug selection in #MDS
We spoke to Shahram Kordasti (@KingsCollegeLon) about the heterogenous immune environment seen in MDS and how to optimize drug selection: http://ow.ly/rj6750EF8Sr
@KordastiL #ESHMDS2021 @ESHaematology #HemOnc #MDSsm #ImmunoOnc
The 2021 #MDS armamentarium
Felicitas Thol discusses the current treatment landscape for high- and low-risk MDS: http://ow.ly/zPcY50EF8Fc
#ESHMDS2021 @ESHaematology #HemOnc #MDSsm
Tackling lower-risk MDS in 2021 - luspatercept, imetelstat & roxadustat.
Learn more with Valeria Santini of @UNI_FIRENZE: http://ow.ly/PEwV50EBtsO
#ESHMDS2021 @ESHaematology #HemOnc #MDSsm
For British Science Week 2021, we’re sharing talks from UK experts all week!
Today, hear from @KordastiL of @G_ICEMD on immune dysregulation and drug selection in #MDS:
http://ow.ly/YcFL50DQ3uw
#BSW21 @WeHCScientists @ScienceWeekUK #IAMRESILIENT2021 #ESHMDS2021 #HemOnc #MDSsm
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
